Arbutus Biopharma Corp ABUS

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Arbutus Biopharma Corporation ("Arbutus", the "Company", "we", "us", and "our") is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).

We continue to protect and defend our intellectual property, which is the subject of our ongoing lawsuit against Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech) for their use of our patented lipid nanoparticle (LNP) technology in their COVID-19 messenger ribonucleic acid interference (mRNA)-LNP vaccines. The court issued a claim construction ruling in September 2025, which construed the disputed claim terms in a manner we generally consider to be favorable. The parties are awaiting further scheduling in the litigation.

Last close 4.20 2026-10-23
Market cap $831.0M 2026-06-30 share count
52-week range 3.50 - 5.45

Valuation FY2025 figures against the last close

P/S59.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.17

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $14.1M$6.2M$18.1M$39.0M$11.0M$6.9M$6.0M$5.9M$10.7M$1.5M
R&D $25.2M$54.0M$73.7M$84.4M$65.5M$49.3M$57.6M$57.9M$62.7M$61.3M
SG&A $15.9M$22.1M$22.5M$17.8M$17.1M$14.8M$17.7M$16.0M$16.1M$39.4M
Total operating expenses $52.2M$82.5M$96.2M$104.5M$84.5M$64.7M$149.9M$95.7M$121.6M$493.1M
Operating income -$38.2M-$76.3M-$78.1M-$65.5M-$73.5M-$57.8M-$143.9M-$89.8M-$110.9M-$491.6M
Interest expense $97.0K$137.0K$459.0K$1.7M$2.9M$4.0M$2.1M$226.0K$261.0K$0
Pre-tax income -$33.5M-$69.9M-$72.8M-$65.0M-$76.2M-$63.7M-$166.4M-$61.3M-$108.7M-$489.2M
Income tax $0$0$0$4.4M$0$0$12.7M$4.3M$24.3M$105.0M
Net income -$33.5M-$69.9M-$72.8M-$69.5M-$76.2M-$63.7M-$153.7M-$57.1M-$84.4M-$384.2M
EPS, basic -0.17-0.38-0.44-0.46-0.83-1.00—-1.21-1.56-7.24
EPS, diluted -0.17-0.38-0.44-0.46-0.83-1.00-2.89-1.21-1.56-7.24
Shares, diluted (wtd. avg.) 191.6M185.6M166.0M150.9M106.2M75.8M—55.3M54.7M53.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $18.0M$36.3M$26.3M$30.8M$109.3M$52.3M$31.8M$36.9M$54.3M$23.4M
Short-term investments $73.5M$86.3M$99.7M$116.1M$46.0M$71.0M$59.0M$87.7M$72.1M$107.1M
Receivables $1.4M$2.4M$1.8M$1.4M$899.0K$1.3M$1.2M$1.4M$402.0K$273.0K
Total current assets $94.5M$127.3M$132.0M$151.1M$160.7M$127.7M$93.8M$129.2M$129.4M$132.6M
Property, plant and equipment $32.0K$3.3M$4.7M$5.1M$6.0M$6.9M$8.7M$10.1M$12.2M$6.9M
Goodwill ——————$0$22.5M$24.4M$24.4M
Other intangibles ——————$0$43.8M$58.6M$99.4M
Total assets $94.6M$131.7M$144.4M$195.4M$204.5M$137.1M$105.5M$227.9M$237.2M$275.9M
Accounts payable $5.5M$7.6M$10.3M$16.0M$10.8M$9.2M$7.2M$9.4M$10.6M$9.9M
Total current liabilities $6.0M$15.6M$22.5M$32.9M$11.2M$9.5M$7.8M$11.2M$14.6M$10.6M
Long-term debt $0$0$0$0$0—————
Total liabilities $18.0M$34.3M$38.4M$58.6M$35.0M$35.1M$32.8M$27.7M$54.7M$72.9M
Retained earnings -$1.38B-$1.35B-$1.28B-$1.20B-$1.13B-$1.05B-$970.1M-$805.2M-$738.1M-$652.7M
Total equity $76.6M$97.4M$106.0M$136.9M$169.4M$102.0M$72.7M$200.2M$182.5M$203.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$39.6M-$64.8M-$85.9M-$35.4M-$67.5M-$51.4M-$71.0M-$67.9M-$48.6M-$57.9M
Depreciation and amortisation $363.0K$1.4M$1.4M$1.4M$1.8M$2.0M$2.0M$2.2M$2.0M$1.1M
Stock-based compensation $7.0M$9.0M$9.3M$7.2M$6.4M$6.2M$6.8M$6.2M$15.1M—
Capital expenditure $0$182.0K$1.0M$512.0K$809.0K$229.0K$589.0K$1.1M$7.3M$4.0M
Investing cash flow $15.6M$22.9M$50.8M-$74.9M-$12.7M-$14.9M$28.3M-$4.1M$27.8M-$99.1M
Financing cash flow $5.7M$52.0M$30.6M$31.8M$137.2M$86.7M$37.5M$55.6M$49.3M$12.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-014623.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -400M -200M 0 200M Revenue, FY2016: 1.5M Net income, FY2016: -384.2M Revenue, FY2017: 10.7M Net income, FY2017: -84.4M Revenue, FY2018: 5.9M Net income, FY2018: -57.1M Revenue, FY2019: 6M Net income, FY2019: -153.7M Revenue, FY2020: 6.9M Net income, FY2020: -63.7M Revenue, FY2021: 11M Net income, FY2021: -76.2M Revenue, FY2022: 39M Net income, FY2022: -69.5M Revenue, FY2023: 18.1M Net income, FY2023: -72.8M Revenue, FY2024: 6.2M Net income, FY2024: -69.9M Revenue, FY2025: 14.1M Net income, FY2025: -33.5M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.5M $10.7M $5.9M $6.0M $6.9M $11.0M $39.0M $18.1M $6.2M $14.1M
Gross profit — — — — — — — — — —
Net income -$384.2M -$84.4M -$57.1M -$153.7M -$63.7M -$76.2M -$69.5M -$72.8M -$69.9M -$33.5M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event Item 8.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%